At a glance

Getting Ahead Together means preventing disease as well as treating it.

Globally, our portfolio spans vaccines, specialty and general medicines, with R&D focused on science of the immune system, human genetics and advanced technologies. 

scientist walking down lab hallway

GSK has a significant footprint in the US across commercial, R&D, manufacturing, and corporate functions.  

  • We employ ~15,000 people across the US
  • Our largest US-based operation, the Upper Providence R&D hub features 8 smart labs and more than 3,000 GSK people discovering and developing new medicines which will change lives.  
  • We also do Research & Development in Boston, Massachusetts, San Francisco, California and Rockville, Maryland. 
  • We have manufacturing sites across the US, including sites in Rockville, Maryland, Upper Merion, Pennsylvania and Zebulon, North Carolina producing medicines to treat diseases such as multiple myeloma, severe eosinophilic asthma, lupus, and HIV and a manufacturing site in Hamilton, Montana contributing to vaccine manufacturing.
  • We have two commercial hubs in Durham, North Carolina and Philadelphia, Pennsylvania. These hubs feature modern, flexible workspaces that provide a hybrid solution to remote and office working – offering our employees opportunities to balance work and home life by creating schedules that flex to personal and business needs.  

 

The United States is a key market for GSK, with sales of $19.6bn in 2023

Over the last 3 years we have brought several important new innovative medicines to patients in the US. including treatments for oncology (Blenrep & Zejula), HIV (Apretude), and Covid (Sotrovimab).  

We operate responsibly for all our stakeholders by prioritizing Innovation, Performance and Trust.  

We are working closely with our colleagues in R&D at our site in Upper Merion, Pennsylvania by investing in state-of-the-art manufacturing to deliver innovation and medicines (JEMPERLI and Depemokimab) to patients more quickly. 

male walking over bridge in the office

Creating a culture where individuals and teams thrive

We are also transforming our culture to create an environment where individuals and teams are inspired to be ambitious for patients, accountable for impact, and to do the right thing, for each other, our communities, society as a whole and always for the patients we serve. Diverse perspectives lead to fresh, innovative ideas. We’re building an inclusive culture where the world’s talent can help transform medicine, together.

  • We have improved diversity, equity, and inclusion by recruiting and appointing diverse talent that mirrors the communities in which we live, work, and serve. By the end of 2023, 35.7% of senior leaders in the US were ethnically diverse at VP and above, compared with 31.3% in 2022.
  • We had 8.1% Black or African American leaders at VP-and-above compared with 8.6% in 2022. We had 6.4% Hispanic or Latinx leaders at VP-and-above compared with 6.4% in 2022. 
  • In 2020, we committed $10 million over 10 years to support the number of women and Black and Latinx students in Philadelphia entering STEM careers. More than 138,000 students of all backgrounds have benefited from GSK STEM equity grants provided to local non-profit organizations so far. 
  • In the US, we continue to engage with Historically Black Colleges and Universities, and Hispanic Serving Institutions, and our employee alumni, to
    encourage applications for our graduate and experienced hire positions and target recruitment campaigns to reach under-represented groups.
female in the office talking to other colleague.

Contributing to public health

Underpinning these changes, we are committed to engage and confront some of the biggest public health challenges facing the US. 

 

  • Contributing to public health

    • Underpinning these changes, we are committed to engage and confront some of the biggest public health challenges facing the US.

  • COVID

    • Over the last two years we have played a key role to develop treatments and vaccines against COVID. Through a partnership with Vir Biotechnology we have developed, and contracted, with the US Government for approximately $1 billion for our monoclonal antibody, Sotrovimab, which demonstrated it can reduce hospitalization and risk of death by 79% in adults with mild-to-moderate COVID-19 who are at high risk of progression to severe disease.

  • Antimicrobial resistance (AMR)

    • This is an urgent threat to public health. By undermining the effectiveness of antibiotics, it currently contributes to 700,000 deaths every year globally, a figure that is expected to increase significantly unless action is taken. We’re focusing on organisms with the highest risk of developing AMR as characterized by the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO).

  • Pricing

    • GSK is committed to responsible pricing as demonstrated through our actions and track record over time. In fact, our average net price for GSK and ViiV products (price after discounts, rebates or other allowances) in the US decreased about 1.9% on average annually over the past five years

  • Patient Assistance Programs

    • During 2021, GSK provided prescribed vaccines and medicines to more than 87,000 low-income uninsured, underinsured, and Medicare Part D patients through GSK and ViiV Healthcare’s Patient Assistance Programs Foundation

    • Therapeutic areas in the Patient Assistance Programs include respiratory, immunology, oncology, vaccines and HIV. Significant product additions in 2021 include Cabenuva and Apretude.
    • Charitable donations through the Patient Assistance Programs Foundation are available in all 50 States, Washington, DC, Puerto Rico, and the US Virgin Islands

    The Wholesale Acquisition Cost (WAC) -- which is the manufacturer’s list price for a drug or biological to wholesalers or direct purchasers -- in the US for GSK contributed products during 2021 was $494 million and for ViiV products was $96 million. The total WAC Value was $590 million.

  • Vaccine hesitancy

    • To raise awareness of the serious nature of shingles – which will impact 1 in 3 adults – GSK and the International Federation on Ageing (IFA) collaborated in 2022 to launch the first ever Shingles Awareness Week. The goal of Shingles Awareness Week is to grow the understanding of the impact of the virus and to dispel common misconceptions regarding the risks of infection.

You might also like

3D rendering of immuno-oncology cells

Company

We unite science, technology and talent to get ahead of disease together
Scientist at a computer monitor looking at 3D images in high throughput screening lab

Innovation

Innovation is at the heart of achieving our purpose
female scientist in lab.

Products

Learn more about our product portfolio and how we're prioritizing vaccines and specialty medicines to get ahead of disease together

Continue to Purpose, strategy and culture